%0 Journal Article
%T Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma
%A Rui Bergantim
%A Fernanda Trigo
%A Jos¨¦ E Guimar£¿es
%J Experimental Hematology & Oncology
%D 2012
%I BioMed Central
%R 10.1186/2162-3619-1-35
%X We retrospectively analysed data from 85 patients with MM submitted to ASCT in our centre from 2000 to 2010: 132 ASCT were realized, 80 of them as tandem.After induction, 17.6% were in complete remission (CR), 41.2% in very good partial remission (VGPR) and 41.2% in partial remission (PR). After transplant 44.7% were in CR, 15.3% in VGPR and 40% in PR. With 22 months (range ¨C 3 to 117 months) of median follow-up, median overall survival (OS) was 43 months and progression-free survival (PFS) 22 months. At 5 years, OS was 45.3% (36.7-53.9%, 95%) and PFS 24.5% (18-31%, 95%). Patients with CR after ASCT had significantly longer PFS as compared to patients with PR (27 vs 7 months; p£¿=£¿0.034) but not when compared to patients with VGPR (27 vs 19 months, p£¿=£¿0.485). The tandem approach represented an advantage in OS and PFS when compared to only one ASCT (31 vs 19 months - p£¿=£¿0.018, and 40 vs 31 - p£¿=£¿0.04, respectively).Our results highlight the impact of response to transplant in patients PFS and tandem modality showed to carry better PFS and OS then the single transplant.Multiple Myeloma (MM) is a neoplasm characterized by abnormal proliferation of plasma cells and secretion of monoclonal immunoglobulin in blood and/or urine [1,2]. It is responsible for 1% of cancers in general and 10-15% of hematologic, accounting for 20% of all deaths due to hematologic malignancies. It affects 4.3/100000 persons per year worldwide and the incidence increases with age (median age 65 years). Around 90% of cases occur after the age of 50. It is more common in male than females (1.4:1) and in Afro-Americans compared to Caucasians (2:1) [1,3].Signs and symptoms vary greatly and clinical presentation may range from cases that are detected on routine screenings to severe hematologic emergencies [1]. In addition to the classic prognostic classification systems DurieSalmon Staging (DSS) [4] and International Staging System (ISS) [5], currently the stratification risk according to cytogenetic
%K Multiple myeloma
%K Bone marrow transplantation
%K Autologous stem cell transplant
%K Tandem transplant
%U http://www.ehoonline.org/content/1/1/35